Literature DB >> 20532811

Apoptotic factors (Bcl-2 and Bax) and diabetic retinopathy in type 2 diabetes.

Taoufik Khalfaoui1, Nuria Basora, Amel Ouertani-Meddeb.   

Abstract

The expression of apoptotic factors Bcl-2 and Bax were studied in the conjunctiva of diabetic patients with and without retinopathy. All patients underwent a complete ophthalmic examination including ocular fundus and retinal fluorescein angiography. The indirect immunoperoxidase method was performed on 15 normal conjunctiva taken during cataract surgery (group 1), on 40 eyes of 40 patients with type 2 diabetes without diabetic retinopathy (group 2) and 13 eyes of 13 patients with diabetic retinopathy (group 3). In normal human conjunctiva, Bax showed positive expression in epithelial, vascular and stromal cells whereas Bcl-2 staining was negative. In the conjunctiva of diabetic patients without diabetic retinopathy, Bax was widely, and strongly, expressed in epithelial cells, vascular endothelial cells, fibroblasts and infiltrating cells such as macrophages. For patients with diabetic retinopathy, Bax was consistently strong to very strong. Bcl-2 protein expression became weak to negative for diabetic patients both with and without diabetic retinopathy. Immunoreactivity was not correlated between Bcl-2 and Bax in the conjunctiva of diabetic patients. Bax was always localized in tissues characterized by a high rate of apoptosis, whereas, Bcl-2 was absent. Our results suggest that diabetic human conjunctiva, with its inflammatory phenomena, is considered as a privileged target for programmed cell death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20532811     DOI: 10.1007/s10735-010-9271-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  57 in total

1.  Is diabetic retinopathy an inflammatory disease?

Authors:  A P Adamis
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Retinopathy in diabetes.

Authors:  Donald S Fong; Lloyd Aiello; Thomas W Gardner; George L King; George Blankenship; Jerry D Cavallerano; Fredrick L Ferris; Ronald Klein
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 3.  [Age-related macular degeneration and apoptosis].

Authors:  W-M Haddad; G Coscas; G Soubrane
Journal:  J Fr Ophtalmol       Date:  2003-03       Impact factor: 0.818

4.  Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax.

Authors:  Zhi Zhang; Suzanne M Lapolla; Matthew G Annis; Mary Truscott; G Jane Roberts; Yiwei Miao; Yuanlong Shao; Chibing Tan; Jun Peng; Arthur E Johnson; Xuejun C Zhang; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

Review 5.  Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities.

Authors:  J C Reed
Journal:  Cell Death Differ       Date:  2006-06-02       Impact factor: 15.828

6.  Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

Authors:  A J Barber; E Lieth; S A Khin; D A Antonetti; A G Buchanan; T W Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  Expression of apoptosis markers in the retinas of human subjects with diabetes.

Authors:  Ahmed M Abu-El-Asrar; Lieve Dralands; Luc Missotten; Ibrahim A Al-Jadaan; Karel Geboes
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-08       Impact factor: 4.799

8.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

9.  Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients.

Authors:  Lidia Kria; Taoufik Khalfaoui; Ghada Mkannez; Omar Beltaief; Raja Anane; Khalil Errais; Lilia Tounsi; Raja Zhioua; Sarra Ben Jilani; Amel Meddeb Ouertani
Journal:  J Mol Histol       Date:  2006-02-16       Impact factor: 2.611

10.  Overexpression of p53 tumor suppressor gene in pterygia.

Authors:  O Weinstein; G Rosenthal; H Zirkin; T Monos; T Lifshitz; S Argov
Journal:  Eye (Lond)       Date:  2002-09       Impact factor: 3.775

View more
  6 in total

1.  MicroRNA-27a protects retinal pigment epithelial cells under high glucose conditions by targeting TLR4.

Authors:  Xiaolei Tang; Yan Dai; Xiaoli Wang; Jian Zeng; Guirong Li
Journal:  Exp Ther Med       Date:  2018-05-10       Impact factor: 2.447

2.  Silencing of insulin receptor substrate-1 increases cell death in retinal Müller cells.

Authors:  Robert J Walker; Nancy M Anderson; Suleiman Bahouth; Jena J Steinle
Journal:  Mol Vis       Date:  2012-02-01       Impact factor: 2.367

Review 3.  Neurodegeneration and Neuroinflammation in Diabetic Retinopathy: Potential Approaches to Delay Neuronal Loss.

Authors:  Joanna Kadłubowska; Lucia Malaguarnera; Piotr Wąż; Katarzyna Zorena
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

4.  Somatostatin protects photoreceptor cells against high glucose-induced apoptosis.

Authors:  Ana I Arroba; Aurora Mazzeo; Daniele Cazzoni; Elena Beltramo; Cristina Hernández; Massimo Porta; Rafael Simó; Ángela M Valverde
Journal:  Mol Vis       Date:  2016-12-30       Impact factor: 2.367

5.  Maslinic Acid Protects against Streptozotocin-Induced Diabetic Retinopathy by Activating Nrf2 and Suppressing NF-κB.

Authors:  Nasser A Alsabaani; Osama M Osman; Mohamed A Dallak; Mohamed D Morsy; Hassan A Al-Dhibi
Journal:  J Ophthalmol       Date:  2022-02-28       Impact factor: 1.909

Review 6.  Thymoquinone in Ocular Neurodegeneration: Modulation of Pathological Mechanisms via Multiple Pathways.

Authors:  Nur Musfirah Mahmud; Luminita Paraoan; Nurliza Khaliddin; Tengku Ain Kamalden
Journal:  Front Cell Neurosci       Date:  2022-03-02       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.